--- title: "Mirion Technologies (MIR) Stock Falls As Acquisitions Mask Modest Organic Growth" type: "News" locale: "en" url: "https://longbridge.com/en/news/294388294.md" description: "Mirion Technologies (MIR) stock fell ~1.7% to US$14.30, down over 25% in three months, despite Q2 2026 revenue rising to US$266.8 million and adjusted EBITDA margins expanding by 150 bps. While acquisitions drove top-line growth and free cash flow hit record levels, organic growth remained modest at ~1%. Investors remain cautious due to reliance on M&A, potential margin dilution, and execution risks, leading to share price pressure despite strong backlog and cash generation." datetime: "2026-07-30T15:27:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294388294.md) - [en](https://longbridge.com/en/news/294388294.md) - [zh-HK](https://longbridge.com/zh-HK/news/294388294.md) --- # Mirion Technologies (MIR) Stock Falls As Acquisitions Mask Modest Organic Growth Mirion Technologies stock was slightly in the red by early afternoon on Wednesday, down about 1.7% near US$14.30 after a tough three months that left shares lower by more than 25%. The market reaction looks cautious, yet the headline from this earnings print is clear. The earnings report put a spotlight on margins and cash generation, with adjusted earnings before interest, tax, depreciation and amortisation expanding and adjusted free cash flow hitting one of the strongest first half showings since the company listed. Love the stronger margins and cash generation from Mirion Technologies but concerned about the recent share price pressure? Set a higher bar for your watchlist with our 85 resilient stocks with low risk scores. ## Q2 2026 Earnings Summary - **Q2 2026 Revenue:** US$266.8 million vs. Q2 2025 US$222.9 million (higher year on year) - **Q2 2026 Net Income:** US$7.7 million vs. Q2 2025 US$8.3 million (slightly lower year on year) - **Q2 2026 Basic EPS:** US$0.0315 vs. Q2 2025 US$0.0369 (lower year on year) - **Q2 2026 Adjusted EBITDA Margin:** approximately 25.5% vs. Q2 2025 prior period margin (expanded by approximately 150 bps) Prefer clear visual charts over walls of earnings tables and footnotes? View a concise visual overview of Mirion Technologies valuation in the company report for Mirion Technologies. NYSE:MIR Trailing 12-Month Earnings & Revenue History as at Jul 2026 ## Mirion bull case: backlog, margins and cash tested Optimists argue Mirion is building a higher quality, recurring revenue platform on top of accelerating nuclear demand. The latest quarter gives that view some concrete support. Nuclear and Safety revenue rose to US$186 million with orders in nuclear power up about 50% excluding acquisitions. Backlog moved above US$1.1b and is about 40% higher year on year, with legacy installed base backlog also about 40% higher. That speaks directly to more long term service and project visibility. Adjusted EBITDA margin reached roughly 25.5% and expanded by about 150 bps, while adjusted free cash flow was US$49 million in Q2 and US$60 million year to date, the strongest first half since listing. Medical margins also improved even though revenue was flat to slightly weaker. For the bullish narrative, these are important milestones on mix, margin and cash generation. ## Mirion bear case: growth mix, execution and share price The main pushback is that Mirion is too exposed to nuclear project risk, acquisitive growth and a stretched equity story. Recent results do show some pressure points. Organic revenue was about 1% in Q2, so the 20% top line growth relied heavily on acquisitions. Medical revenue was slightly weaker, with nuclear medicine and dosimetry expectations trimmed, which raises questions about how broad based the growth engine really is. Management also highlighted timing risk on large awards and some margin dilution from Paragon within Nuclear and Safety. The stock is down about 26% over 90 days and about 17% over 30 days, even after a record backlog and reiterated guidance. That suggests investors remain cautious about order conversion, integration and the need for a meaningful second half step up to meet full year targets. After a quarter where Mirion is leaning on acquisitions while organic growth stays modest, and shareholder dilution, debt coverage and one-off items raise questions, it can be hard to judge if recent weakness is just sentiment or a sign of deeper fragility. Review the independent risk analysis for Mirion Technologies which shows 3 important warning signs ## Stay Ahead With Simply Wall St If the mix of stronger margins, cash generation and a weaker recent share price in Mirion Technologies has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and wait for a setup that fits your plan. Once you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the key developments that matter for your holdings. For a longer term view, tap into the Community to see how other investors are thinking about the same risks and potential catalysts. That combination can help you surface hidden upside or early warning signs before the wider market reacts. ## Seeking Alternatives Beyond Mirion Technologies? Fresh ideas can gain momentum fast and the best entry points often pass quietly under the radar for now. Scan these focused stock shortlists before the window drops and act now. - Spot companies with sturdy balance sheets and fewer nasty surprises by reviewing a curated 85 resilient stocks with low risk scores that may hold up better when sentiment turns. - Ride potential AI-driven breakouts while they are still flying under most radars by checking a tight group of 65 profitable AI stocks that aren't just burning cash that already show real earnings power. - Position ahead of possible power grid upgrades by scanning carefully filtered 34 power grid technology and infrastructure stocks where cash flows and infrastructure exposure move together before the crowd catches on. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [MIR.US](https://longbridge.com/en/quote/MIR.US.md) ## Related News & Research - [MIR: Q2 2026 saw double-digit growth in revenue, orders, and backlog, with expanding margins and strong outlook](https://longbridge.com/en/news/294149913.md) - [MIR: Steady profits and high dividends offset a challenging year of underperformance versus the benchmark](https://longbridge.com/en/news/294325677.md) - [REG - TruFin PLC - Results of General Meeting and Tender Offer](https://longbridge.com/en/news/293918638.md) - [Paramount delays closing Warner buyout while judge considers states' challenge](https://longbridge.com/en/news/293855938.md) - [BiomX And Water.IO Agree To Updated Zorronet Acquisition Terms | PHGE Stock News](https://longbridge.com/en/news/294073208.md)